Nervous System Origin Or Derivative Patents (Class 435/368)
-
Patent number: 8673634Abstract: This invention relates generally to methods and compositions for inducing stem cell or progenitor cell differentiation, and more particularly to methods and compositions for inducing differentiation of stem cells and/or progenitor cells into cells that function within the inner ear.Type: GrantFiled: November 15, 2004Date of Patent: March 18, 2014Assignee: Massachusetts Eye & Ear InfirmaryInventors: Huawei Li, Albert Edge, Stefan Heller
-
Patent number: 8673292Abstract: An isolated, pure homogeneous population of mammalian astrocyte restricted precursor cells which is CD44 immunoreactive and which generate astrocytes but not oligodendrocytes is provided. Methods for isolating and using these mammalian astrocyte restricted precursor cells are also provided.Type: GrantFiled: April 30, 2009Date of Patent: March 18, 2014Assignees: University of Utah, The Government of the United States of AmericaInventors: Mahendra S. Rao, Tahmina Mujtaba, Yuan Yuan Wu, Ying Liu
-
Publication number: 20140065669Abstract: A neuroblastoma host cell line for stably expressing human exogenous protein is provided. The cell line is generated by independently integrating control plasmid and switch plasmid into genome of human neuroblastoma SH-SY5Y cells. Upon inserting diseased gene into the above cell line, the cell line thus stably expresses the interested protein by induction, which can be used to study human neurological diseases related to the gene mutation.Type: ApplicationFiled: April 8, 2013Publication date: March 6, 2014Applicant: National Taiwan Normal UniversityInventors: Guey-Jen LEE-CHEN, Li-Ching LEE, Chih-Hsin LIN
-
Patent number: 8658363Abstract: According to one embodiment, a cell for measuring a level of Ah receptor transcriptional activation is provided. The cell is derived from a neural cell. The cell contains a chromosome into which a reporter construct and an Ah receptor gene are introduced. The reporter construct has a sequence represented by SEQ ID NO: 1 and a reporter gene operably linked to the downstream of the nucleotide sequence. The sequence represented by SEQ ID NO: 1 has a recognizing sequence of an Ah receptor and a nucleotide sequence which is operably linked to the downstream of the recognizing sequence and required to initiate transcription.Type: GrantFiled: March 26, 2012Date of Patent: February 25, 2014Assignee: Kabushiki Kaisha ToshibaInventors: Seiko Yoshimura, Saeko Uruno, Eiichi Akahoshi, Mitsuko Ishihara
-
Patent number: 8658152Abstract: Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed.Type: GrantFiled: September 6, 2012Date of Patent: February 25, 2014Assignee: DePuy Synthes Products, LLCInventors: Darin J. Messina, Alexander M. Harmon, Ian R. Harris, Anthony J. Kihm, Sanjay Mistry, Agnieszka Seyda, Chin-Feng Yi, Anna Gosiewska
-
Patent number: 8658424Abstract: A method of differentiating embryonic stem cells into oligodendroglial precursor cells and oligodendroglial cells by culturing a population of cells comprising a majority of cells that are characterized by a neural tube-like rosette morphology and are Pax6+/Sox1+ into a population of cells that are PDGFR?+.Type: GrantFiled: June 28, 2012Date of Patent: February 25, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Su-Chun Zhang, Baoyang Hu, Zhong-Wei Du
-
Patent number: 8647870Abstract: A biological photoreceptor, which is a directly light-controlled ion channel, including (i) an apoprotein and (ii) a light-sensitive polyene covalently bound to the apoprotein, the polyene interacting with the apoprotein and functioning as a direct light-sensitive gate.Type: GrantFiled: April 23, 2012Date of Patent: February 11, 2014Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Peter Hegemann, Georg Nagel, Ernst Bamberg
-
Publication number: 20140038896Abstract: A method of treating increased non-LTR retrotransposition in a cell. The method includes exposing a neural cell to a retrotransposition inhibitor in an amount sufficient to decrease the non-LTR retrotransposition in the neural cell or a progeny of the neural cell. In various embodiments, the non-LTR retrotransposition involves at least one L1 retrotransposon. Also provided is a method of assaying retrotransposition in neural cells. The method includes sorting synchronized neural cells of the same genetic background into single neural cells, and subjecting one or more of the sorted single neural cells to quantitative polymerase chain reaction amplification of at least one retrotransposon. In addition, a method of identifying an inhibitor of retrotransposition and a identifying a neural condition associated with non-LTR retrotransposition are provided.Type: ApplicationFiled: February 3, 2012Publication date: February 6, 2014Applicant: Salk Institute for Biological StudiesInventors: Fred H. Gage, Nicole Coufal, Mike McConnell, Alysson Muotri, Maria C.N. Marchetto
-
Patent number: 8642331Abstract: Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types.Type: GrantFiled: November 2, 2007Date of Patent: February 4, 2014Assignee: Multiple Sclerosis Research Center of New YorkInventors: Saud A. Sadiq, Violaine K. Harris
-
Publication number: 20140011197Abstract: Stem-cell derived human neuronal models that mimic human Alzheimer's disease, including hereditary and sporadic Alzheimer's disease, comprising neural stem cells derived from human induced pluripotent stem cells. Also provided are purified human neurons developed from the neural stem cells that carry genomes from the Alzheimer's disease patients. The human neuronal models are neuronal models for hereditary and sporadic Alzheimer's disease, and are suitable for measurement of key behaviors of the Alzheimer's disease, providing further diagnostic tools for the development of sporadic Alzheimer's disease, and assisting in drug testing for the therapeutic treatment of Alzheimer's disease.Type: ApplicationFiled: August 15, 2013Publication date: January 9, 2014Applicant: The Regents of the University of CaliforniaInventors: Lawrence Goldstein, Mason Israel
-
Publication number: 20140005196Abstract: This invention offers an effective method of inhibiting the expression of apolipoprotein E by mammalian cells. Apolipoprotein E is a protein that plays a significant role in the development of Alzheimer's Disease in humans. The method comprises administering an effective amount of a triarylmethyl amine compound having the general formula: wherein the R1 group may comprise acyclic amines and aliphatic amines. The R2 group may comprise one of three aryl varieties: aryl, substituted aryl, or heterocycle. Triarylamine compounds inhibit apolipoprotein E expression in mammalian cells. In one aspect of the invention the mammalian cells may be human cells, and more specifically may be human brain cells.Type: ApplicationFiled: June 28, 2012Publication date: January 2, 2014Applicants: California State University Fullerton, California State University FresnoInventors: Santanu Maitra, Nilay Patel
-
Patent number: 8617887Abstract: The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.Type: GrantFiled: June 13, 2004Date of Patent: December 31, 2013Assignee: Yeda Research and Development Co. LtdInventors: Michel Revel, Peter Lonai, Rozemari Stirbu Lonai
-
Publication number: 20130344598Abstract: Aspects of implementations wherein reductions in contamination in transplantation cell population are disclosed herein, including incubating a suspended population of live cells in a culture medium with a substrate having surface that promotes cell to cell adhesion. During the process, the incubating is in absence of substantial mechanical disturbance of the culture medium and cells are in the culture medium for a predetermined period of time. A resulting population of cells which is relatively reduced or eliminated in contaminants is taught. Said population of cells may be collectable by centrifugation and is separable from said contaminants by centrifugation.Type: ApplicationFiled: January 24, 2012Publication date: December 26, 2013Applicant: California Stem Cell, Inc.Inventor: Gabriel Nistor
-
Publication number: 20130344603Abstract: In certain embodiments methods are provided for inducing and/or restoring and/or maintaining a non-senescent phenotype, or aspects thereof (e.g., proliferative capacity and/or pluripotency) in a mammalian cell. The methods typically involve reducing the level or activity of SINE/Alu retrotransposon transcripts in the cell in an amount sufficient to induce or restore proliferative capacity and/or pluripotency to said mammalian cell.Type: ApplicationFiled: October 20, 2011Publication date: December 26, 2013Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: Victoria V. Lunyak
-
Publication number: 20130337506Abstract: The present invention is related to a cell culture medium for the expression of a protein, which medium comprises a PAM inhibitor, or a physiological equivalent thereof, and to a cell culture process for the expression of a protein, in which process a PAM inhibitor, or a physiological equivalent thereof, is used (FIG. 1).Type: ApplicationFiled: November 9, 2011Publication date: December 19, 2013Applicant: SANDOZ GMBHInventors: Corinna Sonderegger, Julia Schmutzhard, Christine Heel, Thomas Stangler
-
Patent number: 8609409Abstract: The present invention provides a synthetic cell culture platform, comprising: a two dimensional and/or three dimensional surface comprising peptides conjugated to said surface and methods of using the platform for increasing cell adhesion, stable attachment and/or proliferation of cells grown on the platform and for promoting differentiation of neural stem cells into neurons.Type: GrantFiled: August 29, 2012Date of Patent: December 17, 2013Assignee: Clemson UniversityInventors: Xiaowei Li, Ning Zhang, Xuejun Wen
-
Publication number: 20130330302Abstract: The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.Type: ApplicationFiled: June 12, 2013Publication date: December 12, 2013Applicant: REGENERATIVE RESEARCH FOUNDATIONInventors: Sally Temple, Jeffrey Stern, Enrique L. Salero-Coca
-
Publication number: 20130323229Abstract: The present invention provides a novel method of treatment for treating brain disorders that manifest oxidative stress by providing targeted populations of neurons with the ability to catabolize the acetylated amino acid derivative, N-acetylaspatic acid (NAA) and further supply extraphysiological levels of ATP to neurons via the targeted expression of the NAA catabolic enzyme aspartoacylase (ASPA) in neurons and astrocytes.Type: ApplicationFiled: May 30, 2013Publication date: December 5, 2013Applicant: University of Medicine and Dentistry of New JerseyInventors: Paola Leone, Jeremy Francis
-
Patent number: 8597945Abstract: A method of differentiating embryonic stem cells into ventral spinal progenitor cells is disclosed. In one embodiment, the invention comprises culturing a population of cells comprising a majority of cells that are characterized by an early rosette morphology and are Sox1?/Pax6+ in the presence of retinoic acid, wherein the cells express Hoxb4, but not Otx2 or Bf1.Type: GrantFiled: February 27, 2012Date of Patent: December 3, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Su-Chun Zhang, Xue-Jun Li
-
Publication number: 20130315886Abstract: A method of treating increased non-LTR retrotransposition in a cell. The method includes exposing a neural cell to a retrotransposition inhibitor in an amount sufficient to decrease the non-LTR retrotransposition in the neural cell or a progeny of the neural cell. In various embodiments, the non-LTR retrotransposition involves at least one L1 retrotransposon. Also provided is a method of assaying retrotransposition in neural cells. The method includes sorting synchronized neural cells of the same genetic background into single neural cells, and subjecting one or more of the sorted single neural cells to quantitative polymerase chain reaction amplification of at least one retrotransposon. In addition, a method of identifying an inhibitor of retrotransposition and a identifying a neural condition associated with non-LTR retrotransposition are provided.Type: ApplicationFiled: August 4, 2010Publication date: November 28, 2013Applicant: Salk Institute for Biological StudiesInventors: Fred H. Gage, Nicole Coufal, Michael J. McConnell, Alysson Muotri, Maria C.N. Marchetto
-
Publication number: 20130302889Abstract: The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.Type: ApplicationFiled: July 11, 2013Publication date: November 14, 2013Inventors: Ira B. Black, Dale L. Woodbury, Darwin J. Prockop, Emily Schwarz
-
Patent number: 8580523Abstract: The present invention identified Lmx1a genes, which are expressed in dopaminergic neurons at all differentiation stages, from proliferating dopaminergic neuron progenitor cells before cell cycle exit to cells after cell cycle exit. Lmx1a expression in cells can be used as an indicator when selecting cells suitable for transplantation therapy for neurodegenerative diseases such as Parkinson's disease, and is useful as a marker for screening agents involved in the induction of dopaminergic neuron differentiation.Type: GrantFiled: January 17, 2012Date of Patent: November 12, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani
-
Publication number: 20130288366Abstract: The present invention provides a synthetic cell culture platform, comprising: a two dimensional and/or three dimensional surface comprising peptides conjugated to said surface and methods of using the platform for increasing cell adhesion, stable attachment and/or proliferation of cells grown on the platform and for promoting differentiation of neural stem cells into neurons.Type: ApplicationFiled: August 29, 2012Publication date: October 31, 2013Inventors: Xiaowei Li, Ning Zhang, Xuejun Wen
-
Patent number: 8569056Abstract: A method for producing retinal nerve cells by inducing differentiation of iris pigmented epithelial cells into the retinal nerve cells. In a first method, iris pigmented epithelial cells derived from a mammal and embryo retinal stem cells derived from a bird are co-cultured. In a second method, iris pigmented epithelial cells of a bird or a mammal is isolated, and the iris pigmented epithelial- cells is subjected to adherent culturing. According to these methods, the retinal nerve cells can be produced by using iris pigmented epithelial cells collected from a patient per se. Therefore, there is a possibility that highly effective regenerative medical treatment can be realized.Type: GrantFiled: June 11, 2004Date of Patent: October 29, 2013Assignee: Japan Science and Technology AgencyInventor: Mitsuko Kosaka
-
Publication number: 20130280804Abstract: The present invention relates to the differentiation of human pluripotent cells, including human pluripotent stems cells to produce a self-renewing multipotent neural crest cell population in a single step method without the requirement of isolation of intermediate cells and without appreciable contamination (in certain preferred instances, virtually none) with Pax6+ neural progenitor cells in the population of p75+ Hnk1+ Ap2+ multipotent neural crest-like cells. The multipotent neural crest cell population obtained can be clonally amplified and maintained for >25 passages (>100 days) while retaining the capacity to differentiate into peripheral neurons, smooth muscle cells and mesenchymal precursor cells.Type: ApplicationFiled: December 19, 2011Publication date: October 24, 2013Inventors: Stephen Dalton, Laura M. Menendez
-
Publication number: 20130280803Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: ApplicationFiled: October 5, 2012Publication date: October 24, 2013Inventors: Supama Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Publication number: 20130274114Abstract: This invention generally relates to multipotent stem cell-based research tools. More particularly, the present invention relates to culture systems and 3-dimensional tissue models that may be used for identifying agents useful for treating diseases and conditions and that are suitable for high throughput screening applications. This present invention is based, in part, on the discovery of a method for propagating multipotent stem cells from human skin fibroblasts and subsequently differentiating those multipotent stem cells into cells of any of the three germ layers.Type: ApplicationFiled: September 28, 2012Publication date: October 17, 2013Applicant: SAINT PETER'S UNIVERSITYInventor: LEONARD SCIORRA
-
Publication number: 20130267464Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.Type: ApplicationFiled: December 14, 2012Publication date: October 10, 2013Applicant: NsGene A/SInventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
-
Patent number: 8551783Abstract: The present invention relates to a method for inducing neural differentiation of stem cells. In more detail, the present invention relates to a method for inducing neural differentiation of stem cells by inhibiting both BMP (bone morphogenetic protein) and Activin/Nodal signaling pathways in the stem cells. The present invention allows all types of stem cells to effectively differentiate into neural precursor cells regardless of conventional methods for stem cell differentiation including floating culture and attachment culture. In addition, since the neural precursor cells induced by the present invention may be differentiated into specific cells (e.g., dopaminergic neurons) or oligodendrocytes in higher efficient manner, they may be applied to treatment of incurable nerve diseases (e.g., Parkinson's disease or spinal cordinjury) and further provide fundamental data on new drug development.Type: GrantFiled: August 31, 2010Date of Patent: October 8, 2013Assignee: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Dong-Wook Kim, Dae-Sung Kim
-
Publication number: 20130252330Abstract: We provide IDH1 gene-defective cell lines (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) derived from dissociated human astrocytoma samples. The cells can be used alone or in combination with each other or other cell types as a tool for determining the impact of IDH1R132H on cellular biology, tumorigenesis, and metabolic profiles. The cell lines may be used to test and identify therapeutic targets and to screen for molecular therapeutic agents.Type: ApplicationFiled: October 24, 2011Publication date: September 26, 2013Applicant: Duke UniveristyInventors: Hai Yan, Darell Bigner, Genglin Jin
-
Publication number: 20130236963Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.Type: ApplicationFiled: December 28, 2011Publication date: September 12, 2013Inventors: Hong Zhu, Joanne Wang, Birgitte P.S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
-
Publication number: 20130236465Abstract: The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.Type: ApplicationFiled: October 24, 2011Publication date: September 12, 2013Applicant: SHANGHAI CANCER INSTITUTEInventors: Zonghai Li, Min Zhou, Hai Wang, Bizhi Shi, Shengli Yang, Hongyang Wang, Jianren Gu
-
Patent number: 8524499Abstract: The present invention relates to an enhancer which functions only in human brain and/or spinal cord motor neurons, where the enhancer comprises a nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 10, or SEQ ID NO: 16. The enhancer can be utilized as part of a nucleic acid construct which also has a nucleic acid encoding a marker protein or a therapeutic protein, a 3? control region, and, optionally, a basal promoter, where these components are positioned with respect to one another to permit expression of the marker protein or the therapeutic protein. The enhancer of the present invention is useful in a method of isolating an enriched or purified population of motor neurons from a mixed population of human brain and/or spinal cells. In addition, the enhancer of the present invention can be used in a method of therapeutically targeting motor neurons.Type: GrantFiled: November 9, 2004Date of Patent: September 3, 2013Assignee: Cornell Research Foundation, Inc.Inventors: Steven A. Goldman, Takahiro Nakano
-
Publication number: 20130224162Abstract: The present invention relates to human neural stem cells (NSCs) transfected with a vector comprising a polynucleotide encoding human choline acetyltransferase (ChAT) and thereby stably expressing the human ChAT, a composition for treating Alzheimer disease or for improving a cognitive disorder comprising the human NSCs expressing a human ChAT. The present human NSCs genetically modified to express human ChAT, when transplanted into the brain of the animal AD model, successfully integrated into the host tissues and differentiated into the normal neuronal cells or glial cells. The instant genetically modified human NSCs stably express ChAT in the brain tissue of AD animal and thereby restore the acetylcholine level, and learning and memory function comparable to normal animal. The present genetically modified human NSCs expressing ChAT can be used for the treatment of AD as well as cognitive disorders due to other brain diseases and aging.Type: ApplicationFiled: July 4, 2011Publication date: August 29, 2013Applicant: Chungbuk National University Industry Academic Cooperation FoundationInventors: Yun-Bae Kim, Seung Up Kim
-
Patent number: 8518390Abstract: This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and/or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients.Type: GrantFiled: July 15, 2011Date of Patent: August 27, 2013Assignee: Advanced Technologies and Regenerative Medicine, LLCInventors: Brian C. Kramer, Anthony J. Kihm
-
Patent number: 8513009Abstract: Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media.Type: GrantFiled: January 29, 2009Date of Patent: August 20, 2013Assignee: Geron CorporationInventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
-
Patent number: 8513017Abstract: Methods are described that bias cells, such as potent and multipotent stem cells, by transfection with a nucleic acid sequence, to differentiate to a desired end-stage cell or a cell having characteristics of a desired end-stage cell. In particular embodiments, human neural stem cells are transfected with vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results in a greater percentage of resultant transformed cells, or their progeny, differentiating into a desired end-stage cell or a cell having characteristics of a desired end-stage cell.Type: GrantFiled: December 20, 2011Date of Patent: August 20, 2013Assignee: University of Central Florida Research Foundation, Inc.Inventors: Kiminobu Sugaya, Amelia Marutle, Angel Alvarez
-
Patent number: 8507273Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.Type: GrantFiled: October 24, 2011Date of Patent: August 13, 2013Assignee: The Brigham and Women's Hospital, Inc.Inventors: Markus H. Frank, Mohamed H. Sayegh
-
Patent number: 8501467Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.Type: GrantFiled: December 23, 2009Date of Patent: August 6, 2013Assignee: StemCells California, Inc.Inventors: Lars Wahlberg, Kenneth Campbell, Charlotta Skogh, Cecilia Eriksson, Klas Wictorin
-
Publication number: 20130189725Abstract: The present invention relates to a human in vitro model system of the blood cerebrospinal fluid barrier (BCSFB), to a method for producing said model system, as well as to uses thereof.Type: ApplicationFiled: August 17, 2011Publication date: July 25, 2013Applicant: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventor: Horst Schroten
-
Patent number: 8492149Abstract: The present invention relates to a method for inducing the differentiation of neural progenitors, neurons, and dopaminergic neurons from human embryonic stem cells with high efficiency, in which neural selection can be performed by the selected media and physical methods. The invention has advantages such as higher efficiency, the effect of lowering cost and time, and maintenance of neural progenitors for a longer period of time, as compared to the known methods for inducing the differentiation into neural progenitors, neurons, and dopaminergic neurons. Accordingly, the method can stably generate cells used for treating Parkinson's disease or other nervous system diseases.Type: GrantFiled: June 5, 2007Date of Patent: July 23, 2013Assignee: JE IL Pharmaceutical Co., Ltd.Inventors: Myung Soo Cho, Myung-Hwa Kim, Young-II Moon, Shin Yong Moon, Sun Kyung Oh, Hee Sun Kim, Dong-Wook Kim
-
Patent number: 8492145Abstract: To supply substantially isolated neural cells in a large amount, and to provide an application means for a neuroregenerative medicine or the like for a neurodegenerative disease, a nervous damage or the like. A method for producing a substantially isolated neural cell, comprising the step of carrying out the suspension culture of embryonic stem cells in the presence of an astrocyte conditioned medium or ingredients substantially equivalent to the conditioned medium; and a neural cell obtained thereby; a cell pharmaceutical composition comprising, as an active ingredient, the isolated neural stem cell; and a method for treating a neurodegenerative disease or nervous damage, comprising the step of introducing the neural cell into a neurodegenerative site or a nervous damage site.Type: GrantFiled: June 23, 2003Date of Patent: July 23, 2013Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Takashi Nakayama, Nobuo Inoue, Yasushi Kondo, Yutaka Suzuki
-
Patent number: 8486698Abstract: The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.Type: GrantFiled: September 4, 2007Date of Patent: July 16, 2013Assignees: University of Medicine and Dentistry of New Jersey, Philadelphia Health and Education CorporationInventors: Ira B. Black, Dale L. Woodbury, Darwin J. Prockop, Emily Schwarz
-
Patent number: 8481313Abstract: The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.Type: GrantFiled: April 22, 2009Date of Patent: July 9, 2013Assignee: Regenerative Research FoundationInventors: Sally Temple, Jeffrey Stern, Enrique L. Salero-Coca
-
Publication number: 20130164262Abstract: Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.Type: ApplicationFiled: August 13, 2012Publication date: June 27, 2013Inventors: Patrick Benoit, Patrice Denefle, Michel Perricaudet, M.E. Suzanne Lewis, Michael R. Hayden
-
Patent number: 8465975Abstract: Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of making and using the same, including deriving late stage MNP cells from pluripotent embryonic stem cells, producing high-purity populations of late stage MNP cells, producing populations of viable MNP cells, transporting viable MNP cells, and transplanting MNP cells.Type: GrantFiled: December 13, 2011Date of Patent: June 18, 2013Assignee: California Stem Cell, Inc.Inventor: Aleksandra Jovanovic Poole
-
Patent number: 8460931Abstract: The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof. This invention provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and cells that are generated along the pathway of neural differentiation may be used for: the study of the cellular and molecular biology of human neural development, discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, drug discovery and the development of screening assays for teratogenic, toxic and neuroprotective effects.Type: GrantFiled: January 31, 2012Date of Patent: June 11, 2013Assignee: ES Cell International PTE Ltd.Inventors: Benjamin Eithan Reubinoff, Martin Federick Pera, Tamir Ben-Hur
-
Patent number: 8460651Abstract: The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.Type: GrantFiled: March 16, 2009Date of Patent: June 11, 2013Assignees: Neuralstem, Inc., The Regents of the University of CaliforniaInventors: Martin Marsala, Osamu Kakinohana, Thomas G. Hazel, Karl K. Johe
-
Patent number: 8450110Abstract: The invention provides neuronal progenitor cells, populations and cultures of cells, cell compositions and methods of producing neuronal progenitor cells. Neuronal progenitor cells can be prepared from embryonic stem cells, such as human embryonic stem cells.Type: GrantFiled: March 20, 2012Date of Patent: May 28, 2013Assignee: California Stem Cell, Inc.Inventor: Aleksandra Jovanovic Poole
-
Publication number: 20130129683Abstract: Described are (a) parvovirus variants capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells, and (b) parvovirus variants capable of propagating and spreading through human tumor cells characterized by particular amino acid deletions and/or substitutions, e.g. a deletion of several amino acids in the C-terminus of NS1/middle exon of NS2. A pharmaceutical composition containing such parvoviruses as well as their use for the treatment of cancer, preferably a glioblastoma, is also described.Type: ApplicationFiled: May 9, 2011Publication date: May 23, 2013Applicant: Deutsches KrebforschungszentrumInventors: Jürg Nüesch, Nadja Thomas, Claudia Plotzky, Jean Rommelaere